Despite howls of protest from some stockholders that the offer was too low, virtually all of them have taken advantage of Gilead Sciences’ proposed buyout of Triangle Pharmaceuticals.

Gilead (Nasdaq: GILD) announced Thursday that 97 percent of Triangle’s outstanding shares had been tendered at the $6 per share price offered by Gilead in December. The tender offer expired on Jan. 15.

The deal is worth more than $460 million.

Triangle, which is poised to bring a new AIDS drug (Coviracil) to market in the United States and recently filed for approval to sell it in the European Union, agreed to the buyout offer on Dec. 4. The deal was not challenged by the federal government.

Gilead said the deal should close within a few days and added that Triangle will become a wholly owned subsidiary of Gilead, which is based in Foster City, CA.